Cargando…

The Management of Iron Chelation Therapy: Preliminary Data from a National Registry of Thalassaemic Patients

Thalassaemia and other haemoglobinopathies constitute an important health problem in Mediterranean countries, placing a tremendous emotional, psychological, and economic burden on their National Health systems. The development of new chelators in the most recent years had a major impact on the treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ceci, Adriana, Mangiarini, Laura, Felisi, Mariagrazia, Bartoloni, Franco, Ciancio, Angela, Capra, Marcello, D'Ascola, Domenico, Cianciulli, Paolo, Filosa, Aldo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123832/ https://www.ncbi.nlm.nih.gov/pubmed/21738864 http://dx.doi.org/10.1155/2011/435683

Ejemplares similares

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferipron-desferrioxamine versus deferasirox
por: Pepe, Alessia, et al.
Publicado: (2011)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferiprone-desferrioxamine versus deferipron and desferrioxamine in monotherapy
por: Pepe, Alessia, et al.
Publicado: (2011)

Iron Chelation Therapy in Thalassemia Syndromes
por: Cianciulli, Paolo
Publicado: (2009)

Cardiac iron overload evaluation in thalassaemic patients using T2* magnetic resonance imaging following chelation therapy: a multicentre cross-sectional study
por: Chapchap, Eduardo Cerello, et al.
Publicado: (2023)

Past, present & future scenario of thalassaemic care & control in India
por: Verma, Ishwar C., et al.
Publicado: (2011)

Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy
por: Pepe, Alessia, et al.
Publicado: (2013)

Non-inferiority double-blind randomised controlled trial comparing gabapentin versus tramadol for the treatment of chronic neuropathic or mixed pain in children and adolescents: the GABA-1 trial—a study protocol
por: Kaguelidou, Florentia, et al.
Publicado: (2019)

Dose rationale for gabapentin and tramadol in pediatric patients with chronic pain
por: Healy, Paul, et al.
Publicado: (2023)

Screening of growth hormone deficiency in short thalassaemic patients and effect of L-carnitine treatment
por: Beshlawy, Amal El, et al.
Publicado: (2010)

Increased autophagy leads to decreased apoptosis during β-thalassaemic mouse and patient erythropoiesis
por: Chaichompoo, Pornthip, et al.
Publicado: (2022)

Speckle tracking echocardiography-derived left ventricular global longitudinal strain in ex-thalassaemics
por: Paul, Amal, et al.
Publicado: (2023)

Myocardial iron overload in sickle/thalassemia patients of Italian origin
por: Meloni, Antonella, et al.
Publicado: (2013)

Post-transfusion hepatitis C virus infection among β-thalassaemic individuals with associated clinical parameters
por: Biswas, Aritra, et al.
Publicado: (2018)

Paediatric clinical research in Europe: an insight on experts’ needs and perspectives
por: Ruggieri, Lucia, et al.
Publicado: (2021)

T2* heterogeneity detected by CMR could be related to myocardial iron distribution in Thalassemia patients
por: Positano, Vincenzo, et al.
Publicado: (2009)

The study of sociodemographic profile, Psychiatric disorder, and caregiver burden in Transfusion dependant β Thalassaemic (TDBT) Children and their caregivers
por: Sahu, Samiksha
Publicado: (2022)

Iron Chelators in Treatment of Iron Overload
por: Entezari, Sarina, et al.
Publicado: (2022)

The safety and effectiveness of genetically corrected iPSCs derived from β-thalassaemia patients in nonmyeloablative β-thalassaemic mice
por: Xian, Yexing, et al.
Publicado: (2020)

Paediatric Medicines in Europe: The Paediatric Regulation—Is It Time for Reform?
por: Toma, Maddalena, et al.
Publicado: (2021)

Iron chelation and multiple sclerosis
por: Weigel, Kelsey J., et al.
Publicado: (2014)

Iron Chelation in Local Infection
por: Scott, Cassidy, et al.
Publicado: (2021)

Role of Iron Chelators in Mucormycosis
por: Mahalmani, Vidya, et al.
Publicado: (2021)

Conservative Iron Chelation for Neuroferritinopathy
por: Marchand, Felix, et al.
Publicado: (2022)

Failure of intertrochanteric nailing due to distal nail jamming
por: Maniscalco, Pietro, et al.
Publicado: (2012)

Gene Expression Analysis of nc-RNAs in Bipolar and Panic Disorders: A Pilot Study
por: Bella, Fabrizio, et al.
Publicado: (2023)

Objectives and Methods of Iron Chelation Therapy
por: Hershko, C., et al.
Publicado: (2003)

Iron Chelation Therapy in Myelodysplastic Syndromes
por: Messa, Emanuela, et al.
Publicado: (2010)

Myelodysplastic Syndromes and Iron Chelation Therapy
por: Angelucci, Emanuele, et al.
Publicado: (2017)

Iron chelation in treatment of superficial siderosis
por: Derle, Eda
Publicado: (2018)

Reversing oncogenic transformation with iron chelation
por: Abdelaal, Gina, et al.
Publicado: (2021)

Emerging Roles of the Iron Chelators in Inflammation
por: Di Paola, Alessandra, et al.
Publicado: (2022)

Ethical and procedural issues for applying researcher-driven multi-national paediatric clinical trials in and outside the European Union: the challenging experience of the DEEP project
por: Giannuzzi, Viviana, et al.
Publicado: (2021)

Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry
por: Hoeks, Marlijn, et al.
Publicado: (2020)

Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs
por: Giannuzzi, Viviana, et al.
Publicado: (2017)

A Review on Iron Chelators in Treatment of Iron Overload Syndromes
por: Mobarra, Naser, et al.
Publicado: (2016)

PedCRIN tool for the biosamples management in pediatric clinical trials
por: Giannuzzi, Viviana, et al.
Publicado: (2023)

Chelators in the Treatment of Iron Accumulation in Parkinson's Disease
por: Mounsey, Ross B., et al.
Publicado: (2012)

Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent
por: Lee, Ji Won, et al.
Publicado: (2013)

Oxidation-Induced Degradable Nanogels for Iron Chelation
por: Liu, Zhi, et al.
Publicado: (2016)

The Utility of Iron Chelators in the Management of Inflammatory Disorders
por: Lehmann, C., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lpsjupm3473k5hpm92gf85su3k